Hyperlipidemia - PACE-CME

Episodes 17-32 of 33

Perspectives on the results of recent clinical outcomes trials with EPA prevention
Perspectives on the results of recent clinical outcomes trials with EPA prevention
MinuteCE®
Perspectives on the results of recent clinical outcomes trials with EPA prevention
1.00 program credit
- P. Gabriel Steg, MD
1.00 program credit
MinuteCE®
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
1.00 credit 3 episodes
- Erik Stroes
- P. Gabriel Steg, MD
- Pam R. Taub, MD, FACC, FASPC
1.00 credit 3 episodes
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
MinuteCE®
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
1.00 program credit
Challenges in ASCVD reduction and TG-related risk
Challenges in ASCVD reduction and TG-related risk
MinuteCE®
Challenges in ASCVD reduction and TG-related risk
1.00 program credit
- Erik Stroes
1.00 program credit
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program credit
- Erin Michos
1.00 program credit
The evolving need and challenges to reach LDL-c targets in high-risk patients
The evolving need and challenges to reach LDL-c targets in high-risk patients
MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program credit
- Kausik Ray, MBChB, MD, MPhil
1.00 program credit
PCSK9i: Benefits across the spectrum of cardiovascular disease
PCSK9i: Benefits across the spectrum of cardiovascular disease
MinuteCE®
PCSK9i: Benefits across the spectrum of cardiovascular disease
1.00 program credit
- Fabrice Martens
1.00 program credit
Oral cholesterol-lowering therapies: The basis of prevention
Oral cholesterol-lowering therapies: The basis of prevention
MinuteCE®
Oral cholesterol-lowering therapies: The basis of prevention
1.00 program credit
- Lale Tokgözoğlu, MD
1.00 program credit
MinuteCE®
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
1.00 credit 4 episodes
- Kausik Ray, MBChB, MD, MPhil
- Lale Tokgözoğlu, MD
- Fabrice Martens
- Erin Michos
1.00 credit 4 episodes
Unmet needs in lowering LDL-c
Unmet needs in lowering LDL-c
MinuteCE®
Unmet needs in lowering LDL-c
1.00 program credit
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
1.00 program credit
Exploring the role of a novel CETP inhibitor in lipid management
Exploring the role of a novel CETP inhibitor in lipid management
MinuteCE®
Exploring the role of a novel CETP inhibitor in lipid management
1.00 program credit
- Roxana Mehran, MD
1.00 program credit
New insights on CETP inhibition from genetic research and clinical trials
New insights on CETP inhibition from genetic research and clinical trials
MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program credit
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
1.00 program credit
MinuteCE®
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
1.00 credit 3 episodes
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Roxana Mehran, MD
1.00 credit 3 episodes
Reassessing the role of triglycerides in residual cardiovascular risk
Reassessing the role of triglycerides in residual cardiovascular risk
MinuteCE®
Reassessing the role of triglycerides in residual cardiovascular risk
1.00 program credit
- Richard Hobbs, MD
1.00 program credit
Integrating icosapent ethyl in preventive strategies: Practical guidance
Integrating icosapent ethyl in preventive strategies: Practical guidance
MinuteCE®
Integrating icosapent ethyl in preventive strategies: Practical guidance
1.00 program credit
- Victor Aboyans, MD, PhD
1.00 program credit
MinuteCE®
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
1.00 credit 3 episodes
- Richard Hobbs, MD
- Lale Tokgözoğlu, MD
- Victor Aboyans, MD, PhD
1.00 credit 3 episodes

2/3